Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Jennifer E. Amengual, Hongli Li, Patrick M. Reagan, Tareq Al Baghdadi, Hayder Saeed, Joseph M Unger, Alexey Danilov, Michael Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2024) 144 (Supplement 1): 3123.2.

https://doi.org/10.1182/blood-2024-199784

Published: 2024

Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Blood (2023) 142 (Supplement 1): 610.

https://doi.org/10.1182/blood-2023-180107

Published: 2023

Journal Articles

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Blood (2023) 142 (Supplement 1): 181.

https://doi.org/10.1182/blood-2023-180114

Published: 2023

Journal Articles

Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016

Alexey Danilov, Hongli Li, Mazyar Shadman, Lisa M. Rimsza, Ahmad Zebari, Sonali M. Smith, Michael Leblanc, Jonathan W. Friedberg, Christopher Carlson, Joo Y Song

Blood (2023) 142 (Supplement 1): 4359.

https://doi.org/10.1182/blood-2023-179612

Published: 2023

Journal Articles

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

Deborah M. Stephens, Hongli Li, Heiko Schöder, David J. Straus, Craig H. Moskowitz, Michael LeBlanc, Lisa M. Rimsza, Nancy L. Bartlett, Andrew M. Evens, Ann S. LaCasce, Paul M. Barr, Michael V. Knopp, Eric D. Hsi, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

Blood (2019) 134 (15): 1238–1246.

https://doi.org/10.1182/blood.2019000719

Published: 2019

Includes: Supplemental data

Journal Articles

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Eric D. Hsi, Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, Brad S. Kahl, John P. Leonard, Andrew M. Evens, David W. Scott, Lisa M. Rimsza, Jonathan W. Friedberg

Blood (2019) 133 (16): 1762–1765.

https://doi.org/10.1182/blood-2018-08-870915

Published: 2019

Includes: Supplemental data

Journal Articles

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016

Xiaoyu Qu, Hongli Li, Rita M. Braziel, Verena Passerini, Lisa M. Rimsza, Eric D. Hsi, John P. Leonard, Sonali M. Smith, Robert Kridel, Oliver Press, Oliver Weigert, Michael LeBlanc, Jonathan W. Friedberg, Min Fang

Blood (2019) 133 (1): 81–93.

https://doi.org/10.1182/blood-2018-07-865428

Published: 2019

Includes: Supplemental data

Journal Articles

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Paul M. Barr, Hongli Li, PhD, Richard Burack, MD PhD, Michael LeBlanc, PhD, Sonali M. Smith, MD, Ajay K. Gopal, MD, Justin D. Floyd, DO, Daniel O. Persky, MD, Oliver Press, MD PhD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2016) 128 (22): 614.

https://doi.org/10.1182/blood.V128.22.614.614

Published: 2016

Journal Articles

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Mazyar Shadman, MD MPH, Hongli Li, PhD, Lisa Rimsza, MD, John P. Leonard, MD, Mark S Kaminski, MD, Rita M Braziel, MD, Catherine M. Spier, MD, Ajay K Gopal, MD, David G Maloney, MD PhD, Bruce Cheson, MD, Shaker Dakhil, MD FACP, Michael LeBlanc, PhD, Sonali M. Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD, Oliver Press, MD PhD

Blood (2016) 128 (22): 616.

https://doi.org/10.1182/blood.V128.22.616.616

Published: 2016

Journal Articles

Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis

Blood (2016) 128 (22): 4651.

https://doi.org/10.1182/blood.V128.22.4651.4651

Published: 2016

Journal Articles

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

Xiaoyu Qu, PhD, Hongli Li, PhD, Oliver W Press, MD PhD, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Michael Leblanc, PhD, Eric D. Hsi, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD MMSc, Min Fang, MD PhD

Blood (2015) 126 (23): 2678.

https://doi.org/10.1182/blood.V126.23.2678.2678

Published: 2015

Journal Articles

Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma

Blood (2015) 126 (23): 518.

https://doi.org/10.1182/blood.V126.23.518.518

Published: 2015

Journal Articles

A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806

Daniel O. Persky, MD, Hongli Li, PhD, Lisa M. Rimsza, MD, Paul M. Barr, MD, Leslie L. Popplewell, MD, Charles L. Bane, MD, Ann Von Gehr, MD, Michael Leblanc, PhD, Richard I. Fisher, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 3931.

https://doi.org/10.1182/blood.V126.23.3931.3931

Published: 2015

Journal Articles

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Muhammad A. Mir, Matthew J. Maurer, Steven C. Ziesmer, Susan L. Slager, Thomas Habermann, William R. Macon, Brian K. Link, Sergei Syrbu, Thomas Witzig, Jonathan W. Friedberg, Oliver Press, Michael LeBlanc, James R. Cerhan, Anne Novak, Stephen M. Ansell

Blood (2015) 125 (6): 992–998.

https://doi.org/10.1182/blood-2014-06-583369

Published: 2015

Includes: Supplemental data

Journal Articles

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Daniel O. Persky, Thomas P. Miller, Joseph M. Unger, Catherine M. Spier, Soham Puvvada, B. Dino Stea, Oliver W. Press, Louis S. Constine, Kevin P. Barton, Jonathan W. Friedberg, Michael LeBlanc, Richard I. Fisher

Blood (2015) 125 (2): 236–241.

https://doi.org/10.1182/blood-2014-06-584623

Published: 2015

Journal Articles

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

Eileen P. Smith, MD, Hongli Li, M.S., Jonathan W. Friedberg, MD, Louis Constine, MD, Lisa M. Rimsza, MD, Ginna G. Laport, MD, Leslie L. Popplewell, MD, David G Maloney, MDPhD, Michael Leblanc, PhD, Stephen J. Forman, MD, Richard I. Fisher, MD, Patrick J. Stiff, MD

Blood (2014) 124 (21): 676.

https://doi.org/10.1182/blood.V124.21.676.676

Published: 2014

Journal Articles

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Daniel O Persky, MD, Thomas P. Miller, MD, Joseph M Unger, PhD, Catherine M. Spier, MD, Soham D. Puvvada, MD, B. Dino Stea, MDPhD, Oliver W. Press, MD PhD, Louis Constine, MD, Kevin Barton, MD, Michael LeBlanc, PhD, Sonali Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 4414.

https://doi.org/10.1182/blood.V124.21.4414.4414

Published: 2014

Journal Articles

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

Brian G. Till, MD, Hongli Li, M.S., Steven H. Bernstein, MD, Richard I. Fisher, MD, Richard Burack, MDPhD, Lisa M. Rimsza, MD, Justin Floyd, DO, Marco A. DaSilva, MD, Dennis F. Moore, MD, Michael LeBlanc, PhD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 149.

https://doi.org/10.1182/blood.V124.21.149.149

Published: 2014

Journal Articles

MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704

Soham D. Puvvada, MD, Patrick J Stiff, MD, Michael Leblanc, PhD, James R. Cook, MD PhD, Brad Kahl, MD, Hongli Li, M.S., Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD, Sonali M. Smith, MD

Blood (2014) 124 (21): 1710.

https://doi.org/10.1182/blood.V124.21.1710.1710

Published: 2014

Journal Articles

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

James R. Cook, MD, PhD, Bryan H. Goldman, MS, Raymond R. Tubbs, DO, Michael LeBlanc, PhD, Lisa M. Rimsza, MD, Patrick Stiff, MD, Richard I Fisher, MD

Blood (2012) 120 (21): 543.

https://doi.org/10.1182/blood.V120.21.543.543

Published: 2012

NARROW

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma

A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only